外周血CK20、uPA mRNA在肺腺癌胸腔积液患者合并远处转移患者中的作用  

The Role of Peripheral CK20,uPA mRNA in Metastasis of Lung Adenocarcinoma Patients with Malignant Pleural Effusion

作　　者：龚磊[1] 黄志煜[1] 杨海燕[1] 雷涛[1] 余海峰[1] 缪璐璐[1] 胡小云[1] 范云[1] 

机构地区：[1]浙江省肿瘤医院,浙江省胸部肿瘤(肺,食管)诊治技术研究重点实验室,浙江杭州310022

出　　处：《中国肿瘤》2013年第11期922-925,共4页China Cancer

摘　　要：[目的]探讨细胞角蛋白19（cytokeratin 19,CK 19）mRNA,细胞角蛋白20（cytokeratin20,CK20）mRNA,基质金属蛋白酶9（matrix metalloproteinase 9,MMP9）mRNA,尿激酶型纤溶酶原激活物（urokinase plasminogen activator,uPA）mRNA在肺腺癌胸腔积液患者发生转移的作用。[方法]采用PCR技术和荧光定量RT-PCR检测47例经病理学确诊的肺腺癌合并胸腔积液患者中的CK19、CK20、MMP9、uPA mRNA水平。[结果]47例肺腺癌合并恶性胸腔积液患者CK19 mRNA 0~52 700copies/ml,CK20 mRNA 0~62 900copies/ml。肺腺癌恶性胸腔积液患者合并骨转移者CK20mRNA较无骨转移患者高（1 060 copies/ml vs 566.7 copies/ml,P=0.045）。伴有区域淋巴结转移患者uPA mRNA较无区域淋巴结转移患者高（553.4 copies/ml vs 173.7 copies/ml,P=0.048）。[结论]外周血CK20 mRNA高表达可能使肺腺癌合并胸膜转移患者更易发生骨转移。uPA mRNA表达可能与肺腺癌胸膜转移患者存在区域淋巴结转移相关。[Purpose] To evaluate the role of cytokeratin 19（CK19）mRNA,cytokeratin 20（CK20）mRNA,matrix metalloproteinase-9（MMP9） mRNA and urokinase plasminogen activator（uPA） mRNA in metastasis of lung adenocarcinoma patients with malignant pleural effusion. [Methods]CK19 mRNA,CK20 mRNA,MMP 9 mRNA,uPA mRNA in 47 pathologically proven lung adenocarcinoma patients with malignant pleural effusion were detected by RT-PCR combined with Real Time PCR. [Results] The range of CK19 mRNA and CK20 mRNA in lung adenocarcinoma patients with malignant pleural effusion was 0 ~52 700copies/ml,0 ~62 900copies/ml,respectively.CK20 mRNA median was higher in patients with bone metastasis than that without bone metastasis（1 060 copies/ml vs 566.7 copies/ml,P =0.045）. uPA mRNA median was higher in patients with local lymph node metastasis than that without local lymph node metastasis（553.4 copies/ml vs 173.7 copies/ml,P=0.048）.[Conclusions] High expression of CK20 mRNA in peripheral blood in lung adenocarcinoma patients with malignant pleural effusion is likely to have bone metastasis.uPA mRNA expression might be correlated to local lymph node metastasis.

关 键 词：肺恶性肿瘤 细胞角蛋白 转移 

分 类 号：R734.2[医药卫生—肿瘤]